Royalty Pharma plc (RPRX)

Royalty Pharma plc (RPRX) is a healthcare company (biotechnology) based in the United States. The share price is $68.30, down 0.33% on the day, which values the company at $39.27B. Price as of 17 Nov 2026, 17:23 UTC, from Yahoo Finance.

Key facts

Share price
$68.30−0.33% today
Market value
$39.27B
P/E ratio
44.6×last 12 months
Forward P/E
11.6×
Dividend yield
1.35%
Funk Score
46/100
Against its own history
Well above its usual priceusual price $30.91
200-week average
$36.6386% above

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Royalty Pharma plc in more detail

RPRX trades at 44.6× its last twelve months' earnings, 11.6× next year's expected earnings, 15.0× sales. Measured against its own history, the price is 121% above what its usual multiples would imply ($30.91) — well above its usual price. It sits 86% above its 200-week average of $36.63.

Over the last five fiscal years Royalty Pharma plc has compounded revenue 2.3% a year, earnings per share 6.2% a year. Its Funk Score is 46 out of 100 (financial strength 3.2, profitability 8.1, growth 3.5, value 3.4, each out of 10).

Worth checking: Debt is growing faster than cash flow; Heavy stock-based pay.

5 of the superinvestors tracked here hold RPRX, including Pat Dorsey (8.2% of the portfolio), Samantha McLemore (6.7% of the portfolio), Baillie Gifford team (0.5% of the portfolio).

Superinvestors holding RPRX

5 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:RPRX vs BIIB (Royalty Pharma plc vs Biogen)RPRX vs GEHC (Royalty Pharma plc vs GE HealthCare Technologies)RPRX vs RVMD (Royalty Pharma plc vs Revolution Medicines)RPRX vs ALC (Royalty Pharma plc vs Alcon)RPRX vs IQV (Royalty Pharma plc vs IQVIA Holdings)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

Royalty Pharma plc (RPRX): questions and answers

What is RPRX's P/E ratio?

Royalty Pharma plc trades at 44.6× its last twelve months' earnings and 11.6× next year's expected earnings. At its fiscal year-ends over the past 6 years the P/E ranged from 11.1× to 395.2×, with a median of 24.2×.

What is RPRX's PEG ratio?

Royalty Pharma plc's PEG ratio is 2.10 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Royalty Pharma plc's market cap?

Royalty Pharma plc is valued at $39.27B at a share price of $68.30.

Is RPRX overvalued or undervalued?

Against its own history, RPRX is well above its usual price: the price is 121% above the $30.91 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is RPRX above its 200-week moving average?

Yes. RPRX is 86.5% above its 200-week average of $36.63. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Royalty Pharma plc growing?

Over the last five fiscal years Royalty Pharma plc's revenue grew 2.3% a year and its earnings per share 6.2% a year.

Cite this page

Funkfolio, “Royalty Pharma plc (RPRX) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/RPRX

Underlying data: Yahoo Finance; company filings with the SEC.